Strategies for hepatitis B virus-infected patients in the immune-tolerant phase: complete therapy at the last mile
10.3760/cma.j.cn501113-20240428-00233
- VernacularTitle:免疫耐受期乙型肝炎病毒感染者的抗病毒治疗策略——全治的最后一公里
- Author:
Yang DING
1
;
Qiuju SHENG
;
Xiaoguang DOU
Author Information
1. 中国医科大学附属盛京医院，沈阳 110000
- Keywords:
Hepatitis B virus;
Infection;
Immune tolerantolerant phase;
Treatment;
Strategies
- From:
Chinese Journal of Hepatology
2024;32(5):399-401
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B is mostly a chronic, progressive disease that, if not treated promptly and effectively, can slowly progress to cirrhosis, liver failure, or hepatocellular carcinoma. Therefore, antiviral therapy, i.e., a "complete therapy" strategy, should be started as long as the virus is positive. Immediate antiviral treatment is not recommended for infected patients who are only in the immune-tolerant phase, mainly because of the milder conditions and poor antiviral therapy efficacy, according to antiviral indications in China's Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version). The relevant issues of why hepatitis B virus infection in the immune-tolerant phase is the last mile of "complete therapy," with an emphasis on the disease’s characteristics and antiviral treatment strategies, are discussed here.
